The impact of cell proliferation markers and p53 mutation status on prognosis of non-metastatic colon cancer

J Surg Oncol. 2014 Jun;109(7):665-75. doi: 10.1002/jso.23563. Epub 2014 Jan 24.

Abstract

Background and objectives: We aimed to evaluate the prognostic value of cell cycle proteins and p53 together with clinicopathologic features in non-metastatic resected colon cancer.

Methods: One hundred nine patients who were diagnosed with resected colon cancer between 2006 and 2011 were analyzed retrospectively. Immunohistochemical staining analyses were used to evaluate the expression of cyclins D1 and A, p53 and Ki-67 in tumor tissue.

Results: High cyclin D1 and cyclin A expression was more common in stage II than stage III tumors. Disease recurrence was more frequent in tumors with low cyclin D1 expression (P = 0.05). No significant association was observed between p53, Ki-67 or cyclin A expression and the risk of relapse and/or death. Multivariate analysis showed that the strongest predictor for a shorter disease-free survival period was extracapsular nodal invasion (ECNI).

Conclusions: We were not able to establish a strong association between patient prognosis and cyclins D1 and A, p53 or Ki-67 expression. However, a negative correlation between cyclin D1 and cyclin A expression and disease stage as well as more frequent relapses in patients with low expression of cyclin D1 suggested that cyclins may be predictive for early relapse in non-metastatic colon cancer.

Keywords: cell proliferation markers; colon cancer; p53 mutation; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cell Cycle
  • Cell Proliferation*
  • Colonic Neoplasms / chemistry
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / mortality
  • Colonic Neoplasms / pathology*
  • Cyclin A / analysis
  • Cyclin D1 / analysis
  • Female
  • Genes, p53*
  • Humans
  • Ki-67 Antigen / analysis
  • Male
  • Middle Aged
  • Mutation*
  • Neoplasm Recurrence, Local / etiology
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies

Substances

  • CCND1 protein, human
  • Cyclin A
  • Ki-67 Antigen
  • Cyclin D1